MARINA-OLE

Serial Number 97272570
Registration 7414532
700

Registration Progress

Application Filed
Feb 17, 2022
Under Examination
Aug 23, 2022
Approved for Publication
Jun 28, 2022
Published for Opposition
Jun 28, 2022
Registered
Jun 11, 2024

Trademark Image

MARINA-OLE

Basic Information

Serial Number
97272570
Registration Number
7414532
Filing Date
February 17, 2022
Registration Date
June 11, 2024
Published for Opposition
June 28, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 11, 2024
Registration
Registered
Classes
005 042

Rights Holder

Avidity Biosciences, Inc.

03
Address
10578 Science Drive, Suite 125
San Diego, CA 92121

Ownership History

Avidity Biosciences, Inc.

Original Applicant
03
San Diego, CA

Avidity Biosciences, Inc.

Owner at Publication
03
San Diego, CA

Avidity Biosciences, Inc.

Original Registrant
03
San Diego, CA

Legal Representation

Attorney
Aaron D. Hendelman

USPTO Deadlines

Next Deadline
1775 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-06-11)
Due Date
June 11, 2030
Grace Period Ends
December 11, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

37 events
Date Code Type Description Documents
Jun 11, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jun 11, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 7, 2024 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
May 7, 2024 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Apr 23, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 23, 2024 ALIE A ASSIGNED TO LIE Loading...
Apr 23, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 4, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 21, 2023 GNRT O NON-FINAL ACTION E-MAILED Loading...
Sep 21, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 21, 2023 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Aug 20, 2023 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Aug 20, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Aug 10, 2023 IUAF S USE AMENDMENT FILED Loading...
Aug 10, 2023 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Aug 8, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 4, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Aug 4, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Aug 4, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 15, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 13, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 13, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Feb 13, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 23, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 28, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 28, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 8, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 19, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 11, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 11, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 11, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 22, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 22, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 22, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 21, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 23, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 21, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
First Use Anywhere: Aug 2, 2022
First Use in Commerce: Aug 2, 2022
Class 042
providing medical and scientific research information in the fields of pharmaceuticals and biotechnology
First Use Anywhere: Aug 2, 2022
First Use in Commerce: Aug 2, 2022

Classification

International Classes
005 042